Skip to main content

For Consumers

Janrain User Menu

Search
0 items
Search

You are here

Home
>
Adult Conditions
>
Pain states

Janrain Page Share

Adult Pain Management

Acetaminophen, the active ingredient in TYLENOL®, is identified as a first-line pain relief option by the:

  • American Heart Association8 for patients with, or at high risk for, cardiovascular disease

  • National Kidney Foundation9 for episodic use in patients with underlying renal disease

  • American Geriatrics Society10 for persistent pain, particularly musculoskeletal pain

Osteoarthritis

Proven analgesic efficacy for patients with OA.11,12

Get the facts

Cold & flu

Alleviate fever, body aches, and sore throat.

Recommend effective relief

Headache

Help patients get relief from tension-type headaches.

See why

TYLENOL® PM relieves temporary pain and occassional sleeplessness

Put pain to rest

REFERENCES: 1. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. Hoftiezer JW, O’Laughlin JC, Ivey KJ. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. Gut. 1982;23(8):692-697. 3. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat. 2000;5(2):137-142. 4. US National Library of Medicine. Naproxen. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a681029.html. Revised July 15, 2016. Accessed May 12, 2017. 5. Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications. Ther Clin Risk Manag. 2009;5(1):65-73. 6. Prescott LF, Speirs GC, Critchley JA, Temple RM, Winney RJ. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol. 1989;36(3):291-297. 7. Martin U, Temple RM, Winney RJ, Prescott LF. The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. Eur J Clin Pharmacol. 1991;41(1):43-46. 8. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642. 9. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27:162-165. 10. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346. 11. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol. 1992;19(12):1950-1954. 12. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325(2):87-91.